MAHA Stack
82
synergie
3
2,600
intermediate
May 17, 2026
Aperçu
The MAHA Stack — inspired by RFK Jr.''s "Make America Healthy Again" movement and his public advocacy for peptide access — combines three of the most evidence-backed peptides into a foundational health optimization protocol covering healing, immunity, and cognitive function. After HHS Secretary RFK Jr.'s February 2026 signal of intent to reconsider the restricted peptide list — followed by the FDA formally removing 12 peptides from the Category 2 list in April 2026 (removal is not the same as approval, and the peptides remain under PCAC review) — this combination became one of the most searched peptide stacks online. BPC-157 provides systemic healing support — gut mucosal repair, connective tissue regeneration, anti-inflammatory action, and neurotropic effects across the gut-brain axis. Its broad mechanism makes it a foundational health compound rather than a specialized treatment. Thymosin Alpha-1 is an immune modulator originally isolated from the thymus gland. Unlike crude immune "boosters," it precisely calibrates immune function — enhancing the response against pathogens and abnormal cells while reducing excessive inflammatory signaling that drives autoimmune-type conditions. It activates dendritic cells, NK cells, and T-helper cells while modulating cytokine production. Thymosin Alpha-1 has FDA-approved use in some countries for hepatitis and is extensively studied for chronic fatigue, autoimmune conditions, and cancer immunotherapy support. Semax adds the cognitive and neural component — BDNF upregulation, dopaminergic support, and neuroprotection. This is consistent with the MAHA movement''s emphasis on brain health and cognitive function as core components of overall health. Together, this stack represents a "whole-system" approach: healing the body''s physical tissue, calibrating immune function, and supporting the brain — the three systems most impacted by modern inflammatory lifestyles.
Protocole de dose
250 mcg
par dose
1,500 mcg
par dose
600 mcg
par dose
Objectifs & Preuves
Avertissements
- BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet. Stack peptides individually before combining if new to peptide therapy.
Comments
Sign in to join the discussion
Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.